Efficacy and Safety of Levofloxacin‐ Versus Moxifloxacin‐Based Nitazoxanide Quadruple Therapy as Second‐Line Treatment for <scp> <i>Helicobacter pylori</i> </scp> in Egypt: A Randomized Multicenter Trial
Both nitazoxanide-based quinolone quadruple regimens demonstrated modest but clinically relevant efficacy as second-line therapy. Moxifloxacin showed superior performance in patients with prior levofloxacin exposure. These findings support the use of moxifloxacin-based rescue therapy in settings with high resistance and limited access to bismuth-containing regimens.
Authors
- Amal Mahmoud (ORCID: https://orcid.org/0000-0001-7691-3656)
- Boshra El-Sayed Hussein
- Sherief Abdel Salam
- Ehab F. Moustafa (ORCID: https://orcid.org/0000-0002-9805-3850)
- Maha Elsabaawy (ORCID: https://orcid.org/0000-0002-3110-1547)
- Gasser El-Azab (ORCID: https://orcid.org/0000-0001-6776-1371)
- Mai Magdy
- Fatma O. Khalil (ORCID: https://orcid.org/0000-0002-3157-5232)
- Nariman Zaghloul
- Ayman Mohammed Shamseya
- Sahar M. Hassany (ORCID: https://orcid.org/0000-0003-1772-506X)
- Medhat Assem
- Ahmed Ellakany
- Usama M. Abdelaal
- Ahmed Abuoelhassan
- Mohammed Ezz‐Eldin
Institutions
- Al-Azhar University (EG)
- Tanta University (EG)
- Tanta University Hospital (EG)
- University of Bisha (SA)
- Menoufia University (EG)
- Alexandria University (EG)
- Assiut University (EG)
- Sohag University (EG)
Publication Details
- Journal
- Helicobacter
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1111/hel.70104
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00